Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol

doi:10.1016/0165-1838(88)90130-0

Journal of the Autonomic Nervous System

Volume 24, Issues 1–2, 2 September 1988, Pages 1-14

Journal of the Auton...

https://doi.org/10.1016/0165-1838(88)90130-0 Get rights and content

Abstract

To elucidate the source and physiological significance of plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) as metabolites of noradrenaline (NA), unlabeled and tritium-labeled NA ([³H]NA) were infused into conscious rats and the formation of labeled and unlabeled DHPG and MHPG examined. Animals were pretreated with clorgyline to determine the effects of inhibiting monoamine oxidase type A (MAO-A), with desipramine to determine the effects of blockade of NA neuronal uptake, or with reserpine to determine the effects of interference with vesicular translocation of NA. Inhibition of neuronal uptake prevented the formation of DHPG from exogenous NA and halved the formation of MHPG, indicating that DHPG is derived from NA metabolized intraneuronally and that MHPG is derived from NA metabolized extraneuronally and from DHPG produced intraneuronally. Blockade of vesicular translocation of NA with reserpine increased DHPG formation from exogenous NA by 300% and MHPG formation by 70%, consistent with enhanced availability of NA in the neuronal cytoplasm for metabolism by MAO-A. About 74% of NA recaptured by sympathetic nerves was estimated to be sequestered into storage vesicles. Endogenous DHPG and MHPG were derived mainly (60–70%) from leakage of NA from storage vesicles and to a smaller extent (30–40%) from NA recaptured after exocytotic release. An increased plasma DHPG to NA ratio with no change in the MHPG to NA ratio during infusions of physiologically active NA demonstrated that changes in plasma MHPG do not necessarily follow changes in DHPG. Consideration of the intra- and extraneuronal sources of plasma DHPG and MHPG, their main derivation from NA directly released into the neuronal cytoplasm and the influences of neuronal uptake and translocation of NA into storage vesicles is essential for the correct interpretation of plasma concentrations of these metabolites in the evaluation of sympathetic nervous function.

References (24)

B.M. Eriksson et al.
Liquid chromatographic method for the determination of 3,4-dihydroxyphenylethyleneglycol and 3,4-dihydroxymandelic acid in plasma
J. Chromatogr.
(1987)
J.L. Izzo et al.
Plasma dihydroxyphenyl-glycol (DHPG) in the in vivo assessment of human neuronal noradrenaline metabolism
Life Sci.
(1985)
G.P. Kaplan et al.
Nonneuronal localization of catechol-O-methyltransferase in brain
P.P. Li et al.
Studies on the utility of urinary 3,4-dihydroxyphenylethyleneglycol (DHPG) measurement
Prog. Neuro-Psychopharmacol Biol. Psychiat.
(1985)
M. Scheinin et al.
Measurement of 3-methoxy-4-hydroxyphenylglycol in human plasma with high-performance liquid chromatography using electrochemical detection
Anal. Biochem.
(1983)
A.P. Zavadil et al.
The effect of desmethylimipramine on the metabolism of noradrenaline
Life Sci.
(1984)
G. Eisenhofer et al.
Simultaneous liquid chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase
Clin. Chem.
(1986)
G. Eisenhofer et al.
Dihydroxyphenylglycol and dihydroxymandelic acid during intravenous infusions of noradrenaline
Clin. Sci.
(1987)
G. Eisenhofer et al.
Release, metabolism and intraneuronal disposition of exogenous, endogenous and newly synthesized norepinephrine in the rat vas deferens
J. Pharmacol. Exp. Ther.
(1988)
G. Eisenhofer et al.
Dihydroxyphenylglycol and intraneuronal metabolism of endogenous and exogenous noradrenaline in the rat vas deferens
J. Pharmacol. Exp. Ther.
(1987)

M. Esler

Assessment of sympathetic nervous function in humans from noradrenaline plasma kinetics

Clin. Sci.

(1982)

D.S. Goldstein et al.

Plasma dihydroxyphenylglycol and the intraneuronal disposition of noradrenaline in humans

J. Clin. Invest.

(1988)

Cited by (99)

Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review
2020, Journal of the Neurological Sciences
Frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB) are two common forms of neurodegenerative dementia, subsequent to Alzheimer's disease (AD). AD is the only dementia that includes clinically validated cerebrospinal fluid (CSF) biomarkers in the diagnostic criteria. FTD and DLB often overlap with AD in their clinical and pathological features, making it challenging to differentiate between these conditions.
This systematic review aimed to identify if novel fluid biomarkers are useful in differentiating FTD and DLB from AD. Increasing the certainty of the differentiation between dementia subtypes would be advantageous clinically and in research.
PubMed and Scopus were searched for studies that quantified and assessed diagnostic accuracy of novel fluid biomarkers in clinically diagnosed patients with FTD or DLB, in comparison to patients with AD. Meta-analyses were performed on biomarkers that were quantified in 3 studies or more.
The search strategy yielded 614 results, from which, 27 studies were included. When comparing bio-fluid levels in AD and FTD patients, neurofilament light chain (NfL) level was often higher in FTD, whilst brain soluble amyloid precursor protein β (sAPPβ) was higher in patients with AD. When comparing bio-fluid levels in AD and DLB patients, α-synuclein ensued heterogeneous findings, while the noradrenaline metabolite (MHPG) was found to be lower in DLB. Ratios of Aβ42/Aβ38 and Aβ42/Aβ40 were lower in AD than FTD and DLB and offered better diagnostic accuracy than raw amyloid-β (Aβ) concentrations.
Several promising novel biomarkers were highlighted in this review. Combinations of fluid biomarkers were more often useful than individual biomarkers in distinguishing subtypes of dementia. Considering the heterogeneity in methods and results between the studies, further validation, ideally with longitudinal prospective designs with large sample sizes and unified protocols, are fundamental before conclusions can be finalised.
Normetadrenaline and metadrenaline induce rat thoracic aorta/prostate contraction via α<inf>1D/1A</inf>-adrenoceptor stimulation
2020, European Journal of Pharmacology
Citation Excerpt :
This suggests that normetadrenaline and metadrenaline may act as partial agonists against α1D-adrenoceptors in the urinary tract. In contrast, metadrenaline concentration in pheochromocytoma tissue is over 10,000-fold higher than plasma concentration of metadrenaline (Eisenhofer et al., 1998). Therefore, normetadrenaline and metadrenaline concentrations in the vicinity of pheochromocytoma tissue are likely to be in ranges generating aortic and prostatic contractions.
Certain catecholamine metabolites exert significant pharmacological effects. Herein, we evaluated the pharmacological activities of catecholamine metabolites in the rat thoracic aorta, prostate, and spleen to determine whether these metabolites affect the contractile functions of smooth muscle tissue via direct action on α-adrenoceptors and α-adrenoceptor subtypes. Among the catecholamine metabolites examined, normetadrenaline and metadrenaline (10⁻⁴ M each) produced relatively strong contractions in the rat thoracic aorta. Maximum aortic contractions induced by normetadrenaline (≈70% of phenylephrine (3 × 10⁻⁷ M)-induced contractions) and metadrenaline (≈45%) were significantly smaller than those induced by phenylephrine (≈95%). Normetadrenaline and metadrenaline (10⁻⁴ M each) inhibited phenylephrine (3 × 10⁻⁷ M)-induced aortic contractions, which were not affected by propranolol (10⁻⁶ M), by 5–20%. Normetadrenaline- and metadrenaline (3 × 10⁻⁵ M each)-induced aortic contractions were strongly inhibited by prazosin (10⁻⁸ M; an α₁-adrenoceptor antagonist) and BMY 7378 (10⁻⁸–10⁻⁷ M; a selective α_1D-adrenoceptor antagonist). Metadrenaline (3 × 10⁻⁵ M)-induced aortic contractions were also significantly inhibited by silodosin (10⁻⁹ M; a selective α_1A-adrenoceptor antagonist). Normetadrenaline and metadrenaline (3 × 10⁻⁵ M each) caused silodosin (10⁻⁹ M)-sensitive prostate contractions but did not cause a prominent spleen contraction. Maximum prostate contractions induced by metadrenaline (≈100% of phenylephrine (3 × 10⁻⁵ M)-induced contractions) were nearly identical to those induced by phenylephrine (≈100%) but were significantly larger than those induced by normetadrenaline (≈80%). These findings suggest that normetadrenaline and metadrenaline act as a partial α_1D/α_1A-adrenoceptor agonist and partial α_1D-adrenoceptor/full α_1A-adrenoceptor agonist, respectively, functioning as adrenaline system stabilizers in α_1D/α_1A-adrenoceptor-abundant smooth muscle tissues.
Reduced monoamine oxidase a activity in pregnant smokers and in their newborns
2009, Biological Psychiatry
Citation Excerpt :
Deamination of norepinephrine (NE) and epinephrine by MAOA produces a reactive aldehyde that is reduced to form DHPG intraneuronally, mainly in sympathetic neurons. Sixty percent to 90% of plasma DHPG is derived from intraneuronal NE via oxidative deamination by MAOA (21,22). Monoamine oxidase A activity is accurately reflected by DHPG (23).
Tobacco smoking is associated with reduced monoamine oxidase A (MAOA) activity. Smoking-associated low MAOA activities in pregnancy and in newborns may have negative perinatal and postnatal consequences. We aimed to compare, in everyday clinical conditions, biomarkers of MAOA activity in smoking (SPW) and lifetime nonsmoking pregnant women (NSPW) and in cord blood and to assess the newborns' behavior during the first 48 hours of life.
Thirty SPW and 29 NSPW in their second trimester of pregnancy were included. Plasma MAOA dependent metabolites of norepinephrine: dihydroxyphenylglycol; dopamine: homovanillic and dihydroxyphenylacetic acid; and serotonin: 5-hydroxy-indol acetic acid were measured at the end of the second trimester, at delivery, and in arterial cord blood along with plasma cotinine. The newborns' discomfort was evaluated every 8 hours by a standardized questionnaire.
The SPW smoked, on average, 73 cigarettes per week at the end of second trimester and 80 cigarettes per week at delivery. Mean plasma cotinine was 84 ng/mL, 105 ng/mL, and 95 ng/mL at the end of second trimester, at delivery, and in cord blood, respectively (NSPW < 10 ng/mL). Plasma markers of MAOA activity, in particular those reflecting dopamine's catabolism, were significantly lower in SPW and in the arterial cord blood of their newborns than in NSPW and their newborns. Newborns of SPW showed significantly more facial discomfort than those of NSPW.
Smoking is associated with MAOA inhibition in pregnant women and in their newborns at birth. Further studies are needed to estimate the behavioral significance of these findings.
Oral administration of an AT <inf>1</inf> receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats
2004, Brain Research
Citation Excerpt :
First, we studied the effects of AT1 receptor blockade in SHRs not submitted to administration of central Ang II. The activities of the sympathoadrenal system and the hypothalamic–pituitary–adrenal (HPA) axis were differentially affected; plasma concentrations of catecholamines or DHPG, the main NE metabolite [14], were not substantially modified, but ACTH and corticosterone secretion were significantly decreased. It is possible that AT1 receptor blockade-induced decrease in blood pressure in SHRs produced a reflex sympathoadrenal activation masking the AT1 receptor blockade inhibition of the sympathoadrenal system.
Peripheral and brain angiotensin II AT₁ receptor blockade decreases high blood pressure, stress, and neuronal injury. To clarify the effects of long-term brain Ang II receptor blockade, the AT₁ blocker, candesartan, was orally administered to spontaneously hypertensive rats (SHRs) for 40 days, followed by intraventricular injection of 25 ng of Ang II. Before Ang II injection, AT₁ receptor blockade normalized blood pressure and decreased plasma adrenocorticotropic hormone (ACTH) and corticosterone. After central administration of excess Ang II, the reduction of ACTH and corticosterone release induced by AT₁ receptor blockade no longer occurred. Central Ang II administration to vehicle-treated SHRs further increased blood pressure, provoked drinking, increased tyrosine hydroxylase (TH) mRNA expression in the locus coeruleus, and stimulated sympathoadrenal catecholamine release. Pretreatment with the AT₁ receptor antagonist eliminated Ang II-induced increases in blood pressure, water intake, and sympathoadrenal catecholamine release; inhibited peripheral and brain AT₁ receptors; increased AT₂ receptor binding in the locus coeruleus, inferior olive, and adrenal cortex; and decreased AT₂ receptor binding in the adrenal medulla. Inhibition of brain AT₁ receptors correlated with decreased TH transcription in the locus coeruleus, indicating a decreased central sympathetic drive. This, and the diminished adrenomedullary AT₁ and AT₂ receptor stimulation, result in decreased sympathoadrenomedullary stimulation. Oral administration of AT₁ antagonists can effectively block central actions of Ang II, regulating blood pressure and reaction to stress, and selectively and differentially modulating sympathoadrenal response and the hypothalamic–pituitary–adrenal stimulation produced by brain Ang II—effects of potential therapeutic importance.
NPY and NPY Y<inf>1</inf> receptor effects on noradrenaline overflow from the rat brain in vitro
2004, Regulatory Peptides
Neurotransmitters and neuropeptides play important roles in the regulation of various neuroendocrine functions particularly feeding. The aim of this study was to investigate whether a functional interaction occurs among neuropeptide Y (NPY) at NPY Y₁ receptors and noradrenaline overflow, as this may contribute to the regulation of appetite. The release of endogenous noradrenaline and its metabolite 3,4-dihydroxyphenylglycol (DHPG) were examined from hypothalamic and medullary prisms using the technique of in vitro superfusion and high performance liquid chromatography (HPLC) with coulometric detection. Noradrenaline and DHPG overflow was investigated at rest, in response to NPY (0.1 μM) and in response to the NPY Y₁ receptor agonist, [Leu³¹,Pro³⁴]NPY (0.1 μM). Perfusion with NPY and [Leu³¹,Pro³⁴]NPY significantly reduced noradrenaline overflow from the hypothalamus and medulla. Perfusion with NPY and [Leu³¹,Pro³⁴]NPY was without significant effect on hypothalamic DHPG overflow, while medullary DHPG overflow was significantly reduced by NPY and [Leu³¹,Pro³⁴]NPY. Results from this study provide evidence of NPY Y₁ receptor-mediated inhibition of noradrenaline release in the hypothalamus and medulla, further illustrating a complex interaction between neurotransmitters and neuropeptides within the rat brain.
In vivo assessment of catechol O-methyltransferase activity in rabbit skeletal muscle
2004, Autonomic Neuroscience: Basic and Clinical
With the use of microdialysis technique in the anesthetized rabbit, we examined the catechol O-methyltransferase (COMT) activity at the skeletal muscle interstitium. We implanted a dialysis probe into the adductor muscle, and monitored dialysate catecholamines and their metabolites with chromatogram-electrochemical detection. Administration of COMT inhibitor (entacapone) decreased dialysate 3-methoxy 4-hydroxyphenylglycol (MHPG) levels. Local administration of dihydroxyphenylglycol induced increases in dialysate MHPG levels. These increases in dialysate MHPG levels were suppressed by the addition of entacapone. The concentration of MHPG in the skeletal muscle dialysate corresponded to the COMT activity in the skeletal muscle. Furthermore, local administration of norepinephrine or epinephrine increased normetanephrine or metanephrine levels in dialysate but not MHPG levels. Skeletal muscle microdialysis with local administration of catecholamine offers a new method for in vivo assessment of regional COMT activity.

View all citing articles on Scopus

View full text

Research paperSource and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol

Abstract

J. Chromatogr.

Life Sci.

Prog. Neuro-Psychopharmacol Biol. Psychiat.

Anal. Biochem.

Life Sci.

Simultaneous liquid chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase

Clin. Chem.

Dihydroxyphenylglycol and dihydroxymandelic acid during intravenous infusions of noradrenaline

Clin. Sci.

Release, metabolism and intraneuronal disposition of exogenous, endogenous and newly synthesized norepinephrine in the rat vas deferens

J. Pharmacol. Exp. Ther.

Dihydroxyphenylglycol and intraneuronal metabolism of endogenous and exogenous noradrenaline in the rat vas deferens

J. Pharmacol. Exp. Ther.

Assessment of sympathetic nervous function in humans from noradrenaline plasma kinetics

Clin. Sci.

Plasma dihydroxyphenylglycol and the intraneuronal disposition of noradrenaline in humans

J. Clin. Invest.

Research paper
Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol